Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine

Itzykson, Raphaël; Thépot, Sylvain; Quesnel, Bruno; Dreyfus, François; Beyne‐Rauzy, Odile; Turlure, Pascal; Vey, Norbert; Récher, Christian; Dartigeas, Caroline; Legros, Laurence; Delaunay, Jacques; Salanoubat, Célia; Visanica, Sorin; Stamatoullas, Aspasia; Isnard, Françoise; Marfaing‐Koka, Anne; de Botton, Stéphane; Chelghoum, Youcef; Taksin, Anne‐Laure; Plantier, Isabelle; Amé, Shanti; Boehrer, Simone; Gardin, Claude; Beach, C.L.; Adès, Lionel; Fenaux, Pierre; behalf of the Groupe Francophone des Myelodysplasies (GFM), on

doi:10.1182/blood-2010-06-289280

Public

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine

Published in Blood • Oct 13, 2010

Authors:

Raphaël Itzykson

Sylvain Thépot

Bruno Quesnel

Abstract

Prognostic factors for response and survival in higher-risk myelodysplastic syndrome patients treated with azacitidine (AZA) remain largely unknown. Two hundred eighty-two consecutive high or intermediate-2 risk myelodysplastic syndrome patients received AZA in a compassionate, patient-named program...

Subject

Azacitidine

Myelodysplastic syndromes

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!